GLP1-Injections
US$ 29.79
glp 1 nestle Nestlé Health Science launches GLP-1 Designed By Experts: BOOST® Advanced
Description
Between 43% and 51.5% of participants met criteria for disease resolution, meaning they essentially no longer had clinically significant sleep apnea
Death by any cause was 13% lower among patients treated with GLP-1 receptor agonists
Six RCTs utilized matching placebos [26-29,31,35], four used insulin [33,34,36,37], two employed GLP-1RA [30,32], and one trial included both placebo and GLP-1RA in the control groups [25]
ABC News' Eric Strauss, Michelle Stoddart, Emily Chang and Isabella Murray contributed to this report.
